J
James T. Willerson
Researcher at St Lukes Episcopal Hospital
Publications - 79
Citations - 14597
James T. Willerson is an academic researcher from St Lukes Episcopal Hospital. The author has contributed to research in topics: Myocardial infarction & Revascularization. The author has an hindex of 37, co-authored 79 publications receiving 13769 citations. Previous affiliations of James T. Willerson include University of Texas Health Science Center at Houston & The Texas Heart Institute.
Papers
More filters
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure
Emerson C. Perin,Hans F. Dohmann,Radovan Borojevic,Suzana A. Silva,Andre L.S. Sousa,Claudio Tinoco Mesquita,Maria Isabel D. Rossi,Antonio Carlos Carvalho,Hélio S. Dutra,Hans J.F. Dohmann,Guilherme V. Silva,Luciano Belem,Ricardo Vivacqua,Fernando Oswaldo Dias Rangel,Roberto Esporcatte,Yong-Jian Geng,William K. Vaughn,Joao A.R. Assad,Evandro Tinoco Mesquita,James T. Willerson +19 more
TL;DR: The present study demonstrates the relative safety of intramyocardial injections of bone marrow–derived stem cells in humans with severe heart failure and the potential for improving myocardial blood flow with associated enhancement of regional and global left ventricular function.
Journal ArticleDOI
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Paul M. Ridker,Eleanor Danielson,Francisco Ah Fonseca,Jacques Genest,Antonio M. Gotto,John J.P. Kastelein,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +13 more
TL;DR: For people choosing to start pharmacological prophylaxis, reduction in both LDL cholesterol and hsCRP are indicators of successful treatment with rosuvastatin, and these reductions were predictive of event rates irrespective of the lipid endpoint used.
Journal ArticleDOI
Mesenchymal Stem Cells Differentiate into an Endothelial Phenotype, Enhance Vascular Density, and Improve Heart Function in a Canine Chronic Ischemia Model
Guilherme V. Silva,Silvio H. Litovsky,Joao A.R. Assad,Andre L.S. Sousa,Bradley J. Martin,Deborah Vela,Stephanie Coulter,Jing Lin,Judy Ober,William K. Vaughn,Rodrigo Branco,Edie M. Oliveira,Rumin He,Yong-Jian Geng,James T. Willerson,Emerson C. Perin +15 more
TL;DR: In a canine chronic ischemia model, MSCs differentiated into smooth muscle cells and endothelial cells, resulting in increased vascularity and improved cardiac function in the treated group.
Journal ArticleDOI
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Robert J. Glynn,Eleanor Danielson,Francisco Antonio Helfenstein Fonseca,Jacques Genest,Antonio M. Gotto,John J.P. Kastelein,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Paul M. Ridker +13 more
TL;DR: In a randomized trial of 17,802 apparently healthy men and women with both low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (34 mmol per liter) and high-sensitivity C-reactive protein levels of 20 mg per liter or higher to receive rosuvastatin or placebo.